BR112014022106A2 - derivados macrocíclicos para o tratamento de doenças - Google Patents

derivados macrocíclicos para o tratamento de doenças

Info

Publication number
BR112014022106A2
BR112014022106A2 BR112014022106A BR112014022106A BR112014022106A2 BR 112014022106 A2 BR112014022106 A2 BR 112014022106A2 BR 112014022106 A BR112014022106 A BR 112014022106A BR 112014022106 A BR112014022106 A BR 112014022106A BR 112014022106 A2 BR112014022106 A2 BR 112014022106A2
Authority
BR
Brazil
Prior art keywords
diseases
treatment
compounds
salts
macrocyclic derivatives
Prior art date
Application number
BR112014022106A
Other languages
English (en)
Other versions
BR112014022106B1 (pt
Inventor
Joseph Burke Benjamin
Louise Palmer Cynthia
Jean Cui Jingrong
Charles Kath John
Gail Deal Judith
Raymond Collins Michael
Ann Mctigue Michele
William Sach Neal
Francis Richardson Paul
Thi Quy Le Phuong
Huang Qinhua
Louis Hoffman Robert
Steven Kania Robert
Bailey Simon
Willliam Johnson Ted
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014022106(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR112014022106A2 publication Critical patent/BR112014022106A2/pt
Publication of BR112014022106B1 publication Critical patent/BR112014022106B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo “derivados macrocíclicos para o tratamento de doenças” a invenção refere-se aos compostos de fórmula (f) (f) como adicionalmente definidos no presente documento e os sais farmaceuticamente aceitáveis dos mesmos, a composições farmacêuticas compreendendo tais compostos e sais, e aos usos dos mesmos. os compostos e sais da presente invenção inibem a quinase do linfoma anaplástico (alk) e/ou e ml4-alk e são úteis para o tratamento ou melhoramento de distúrbios proliferativos anormais de células, tais como o câncer.
BR112014022106-5A 2012-03-06 2013-02-20 Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças BR112014022106B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261607485P 2012-03-06 2012-03-06
US61/607.485 2012-03-06
US201361759307P 2013-01-31 2013-01-31
US61/759.307 2013-01-31
PCT/IB2013/051391 WO2013132376A1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
BR112014022106A2 true BR112014022106A2 (pt) 2017-07-11
BR112014022106B1 BR112014022106B1 (pt) 2022-08-02

Family

ID=48142828

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014022106-5A BR112014022106B1 (pt) 2012-03-06 2013-02-20 Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças

Country Status (46)

Country Link
US (2) US8680111B2 (pt)
EP (1) EP2822953B9 (pt)
JP (2) JP5823066B2 (pt)
KR (1) KR101692600B1 (pt)
CN (1) CN104169286B (pt)
AP (1) AP2014007881A0 (pt)
AR (1) AR090230A1 (pt)
AU (1) AU2013229173B2 (pt)
BR (1) BR112014022106B1 (pt)
CA (1) CA2863892C (pt)
CL (1) CL2014002084A1 (pt)
CO (1) CO7061081A2 (pt)
CR (1) CR20140370A (pt)
CY (2) CY1118771T1 (pt)
DK (1) DK2822953T5 (pt)
DO (1) DOP2014000188A (pt)
EA (1) EA026155B9 (pt)
ES (1) ES2621220T3 (pt)
FR (1) FR19C1062I2 (pt)
GE (1) GEP201606560B (pt)
GT (1) GT201400187A (pt)
HK (1) HK1199247A1 (pt)
HR (1) HRP20170287T2 (pt)
HU (2) HUE034118T2 (pt)
IL (1) IL234062A (pt)
LT (2) LT2822953T (pt)
LU (1) LUC00131I2 (pt)
MD (1) MD4590C1 (pt)
ME (1) ME02630B (pt)
MX (1) MX350844B (pt)
MY (1) MY169142A (pt)
NI (1) NI201400102A (pt)
NL (1) NL301006I2 (pt)
NO (1) NO2019034I1 (pt)
NZ (1) NZ627900A (pt)
PE (1) PE20142339A1 (pt)
PH (1) PH12014501992A1 (pt)
PL (1) PL2822953T3 (pt)
PT (1) PT2822953T (pt)
RS (1) RS55814B1 (pt)
SG (1) SG11201404451TA (pt)
SI (1) SI2822953T1 (pt)
TW (1) TWI476199B (pt)
UY (1) UY34657A (pt)
WO (1) WO2013132376A1 (pt)
ZA (1) ZA201406244B (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2953931T1 (sl) 2013-01-31 2017-08-31 Vertex Pharmaceuticals Incorporated Piridon amidi kot modulatorji natrijevih kanalov
ES2656189T3 (es) 2013-06-28 2018-02-26 Pfizer Inc. Formas sólidas de un inhibidor macrocíclico de quinasa
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
EP4338739A3 (en) 2014-01-24 2024-05-29 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
CN103772272A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-溴吡啶的合成方法
JP6609308B2 (ja) * 2014-08-20 2019-11-20 テリジーン リミテッド キナーゼ阻害剤としての置換マクロサイクル
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
US9663535B2 (en) * 2014-10-13 2017-05-30 Atrin Pharmaceuticals LLC Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
KR102595599B1 (ko) 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
BR112017013982A2 (pt) * 2015-01-16 2018-01-02 Chugai Seiyaku Kabushiki Kaisha fármaco de combinação
ES2864839T3 (es) * 2015-07-02 2021-10-14 Turning Point Therapeutics Inc Macrociclos de diarilo quirales como moduladores de proteína quinasas
EP4397665A2 (en) 2015-07-06 2024-07-10 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
CN108026109B (zh) 2015-07-21 2021-03-02 特普医药公司 手性二芳基大环及其用途
CN107849060A (zh) * 2015-07-31 2018-03-27 辉瑞公司 劳拉替尼游离碱的结晶形式
EP3355902B1 (en) 2015-09-30 2022-04-13 Merck Patent GmbH Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
CN108699081B (zh) * 2016-03-03 2019-10-18 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN105732355A (zh) * 2016-04-07 2016-07-06 戊言医药科技（上海）有限公司 1-(5-氟-2-碘苯基)乙酮的制备方法
CN105646355A (zh) * 2016-04-07 2016-06-08 戊言医药科技（上海）有限公司 3-(羟甲基)-1-甲基-吡唑-5-甲腈的制备方法
EP3770164A1 (en) 2016-04-08 2021-01-27 Pfizer Inc Crystalline forms of lorlatinib maleate
WO2017180723A1 (en) * 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
CN105801603B (zh) * 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
CN109715165A (zh) 2016-07-28 2019-05-03 Tp生物医药公司 巨环激酶抑制剂
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018137679A1 (en) * 2017-01-25 2018-08-02 Teligene Ltd Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
WO2019002132A1 (en) 2017-06-30 2019-01-03 Bayer Animal Health Gmbh NEW AZAQUINOLINE DERIVATIVES
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
JP7224334B2 (ja) 2017-07-28 2023-02-17 ターニング・ポイント・セラピューティクス・インコーポレイテッド 大環式化合物およびその使用
SI3694863T1 (sl) 2017-10-10 2023-10-30 Pfizer Inc. Kristalna oblika hidrata proste baze lorlatiniba
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
EP3752152A1 (en) 2018-02-12 2020-12-23 Vertex Pharmaceuticals Incorporated A method of treating pain
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
WO2019209633A1 (en) 2018-04-23 2019-10-31 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
WO2019210835A1 (zh) * 2018-05-04 2019-11-07 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN108621206B (zh) * 2018-05-07 2020-08-14 昆山国显光电有限公司 手套箱系统以及手套箱系统的保养方法
KR20210063332A (ko) * 2018-09-18 2021-06-01 가부시키가이샤 야쿠르트 혼샤 퀴놀린카르복사미드 유도체를 사용하는 암 병용 요법
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN109081810A (zh) * 2018-09-20 2018-12-25 沈阳药科大学 1-甲基-3–((甲氨基)甲基)-1h-吡唑-5-腈的合成方法
JP7347852B2 (ja) * 2018-11-28 2023-09-20 深▲チェン▼市塔吉瑞生物医薬有限公司 重水素化大環状化合物の調製方法
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
CN109651397A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼中间体及制备劳拉替尼的方法
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
CN109651418A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼原料药合成中间体及有机金属钯催化偶联制备劳拉替尼的方法
CN111499514A (zh) * 2019-01-31 2020-08-07 连云港润众制药有限公司 一种罗沙司他中间体的制备方法
WO2020190827A1 (en) * 2019-03-21 2020-09-24 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
EP3844166B1 (en) * 2019-05-14 2023-07-12 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
WO2021011345A1 (en) * 2019-07-18 2021-01-21 Pliva Hrvatska D.O.O Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
EP4041396A1 (en) 2019-10-10 2022-08-17 Sandoz AG Polymorph of lorlatinib
CN112812128B (zh) * 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CN111170908B (zh) * 2020-01-09 2021-08-17 北京印刷学院 一种2，4-二甲基-3-甲磺酰基卤苯的合成方法
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
IL297898A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
PE20230608A1 (es) 2020-05-05 2023-04-13 Nuvalent Inc Quimioterapicos de eter macrociclico heteroaromatico
JP2023529068A (ja) * 2020-05-18 2023-07-07 深▲チェン▼市塔吉瑞生物医薬有限公司 固体形態の大環状化合物、その調製およびその使用
US20230257396A1 (en) * 2020-07-10 2023-08-17 Blossomhill Therapeutics, Inc. Macrocycles and their use
IL303419A (en) * 2020-12-17 2023-08-01 Blossomhill Therapeutics Inc Macrocyclic compounds and their use
CN114805371B (zh) * 2021-01-19 2024-05-24 江苏开元药业有限公司 含2-氨基嘧啶大环类化合物及其制备方法和用途
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115246843A (zh) * 2021-04-26 2022-10-28 苏州东南药业股份有限公司 一类十四元稠环衍生物及其应用
WO2022256622A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
IL311444A (en) * 2021-10-01 2024-05-01 Nuvalent Inc Solid forms, pharmaceutical preparations and preparation of macrocyclic heteroaromatic ether compounds
WO2023156983A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa Compounds and compositions for neurodegenerative diseases
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN115746023A (zh) * 2022-10-27 2023-03-07 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途
WO2024146541A1 (en) * 2023-01-03 2024-07-11 Guangdong Newopp Biopharmaceuticals Co., Ltd. Macrocyclic compounds as usp1 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
RS53118B (en) 2003-02-26 2014-06-30 Sugen Inc. AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
CA2578370A1 (en) 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
KR100859891B1 (ko) * 2004-08-26 2008-09-23 화이자 인코포레이티드 단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
ES2355923T3 (es) 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
PT1959955E (pt) 2005-12-05 2011-01-04 Pfizer Prod Inc Método para tratar o crescimento celular anómalo
CA2632283C (en) 2005-12-05 2011-06-21 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
US8362236B2 (en) 2007-03-01 2013-01-29 Chugai Seiyaku Kabushiki Kaisha Macrocyclic compound
WO2008110918A2 (en) * 2007-03-13 2008-09-18 Pfizer Products Inc. Erythromycin-based macrolides
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
JP2011518836A (ja) * 2008-04-24 2011-06-30 インサイト・コーポレイション 大環状化合物およびそれらのキナーゼ阻害剤としての使用
UA104002C2 (ru) * 2008-06-06 2013-12-25 Санофи-Авентис МАКРОЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ МОЧЕВИНЫ И СУЛЬФАМИДА КАК ИНГИБИТОРЫ TAFIa
EP2334301B1 (en) * 2008-09-08 2018-02-14 Merck Serono SA Macrocyclics pyrimidines as aurora kinase inhibitors
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2490766A1 (en) 2009-10-21 2012-08-29 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
US8916593B2 (en) * 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
MY191934A (en) * 2010-05-20 2022-07-19 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US8975232B2 (en) 2010-07-29 2015-03-10 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
WO2012125603A1 (en) 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors

Also Published As

Publication number Publication date
MD20140086A2 (ro) 2015-01-31
US9133215B2 (en) 2015-09-15
CL2014002084A1 (es) 2014-11-03
LUC00131I1 (pt) 2019-10-11
PT2822953T (pt) 2017-04-06
HUE034118T2 (en) 2018-01-29
HK1199247A1 (zh) 2015-06-26
CY1118771T1 (el) 2017-07-12
IL234062A (en) 2017-08-31
AU2013229173A1 (en) 2014-08-21
MD4590C1 (ro) 2019-03-31
EA026155B1 (ru) 2017-03-31
FR19C1062I2 (fr) 2020-09-04
US20130252961A1 (en) 2013-09-26
MX2014010716A (es) 2014-09-22
DOP2014000188A (es) 2014-11-16
SG11201404451TA (en) 2014-09-26
SI2822953T1 (sl) 2017-04-26
PH12014501992B1 (en) 2014-11-24
NO2019034I1 (no) 2019-08-19
CY2019033I2 (el) 2019-11-27
JP2016041709A (ja) 2016-03-31
JP6002825B2 (ja) 2016-10-05
EA026155B9 (ru) 2017-06-30
DK2822953T5 (en) 2017-09-11
CA2863892C (en) 2016-08-30
US20140135339A1 (en) 2014-05-15
CN104169286B (zh) 2016-06-08
ES2621220T9 (es) 2017-11-23
CN104169286A (zh) 2014-11-26
TWI476199B (zh) 2015-03-11
PH12014501992A1 (en) 2014-11-24
AP2014007881A0 (en) 2014-08-31
MD4590B1 (ro) 2018-08-31
MX350844B (es) 2017-09-22
EP2822953B9 (en) 2017-06-21
NL301006I2 (nl) 2020-04-14
US8680111B2 (en) 2014-03-25
LUC00131I2 (pt) 2020-07-16
HRP20170287T1 (hr) 2017-04-21
LTC2822953I2 (lt) 2020-12-28
HUS1900040I1 (hu) 2019-09-30
GEP201606560B (en) 2016-10-25
UY34657A (es) 2013-10-31
AU2013229173B2 (en) 2017-06-01
EA201491394A1 (ru) 2015-05-29
TW201350484A (zh) 2013-12-16
WO2013132376A1 (en) 2013-09-12
CY2019033I1 (el) 2019-11-27
JP2015510879A (ja) 2015-04-13
PL2822953T3 (pl) 2017-07-31
KR20140137414A (ko) 2014-12-02
KR101692600B1 (ko) 2017-01-03
CA2863892A1 (en) 2013-09-12
AR090230A1 (es) 2014-10-29
LTPA2019519I1 (lt) 2019-11-11
EP2822953B1 (en) 2017-02-01
MY169142A (en) 2019-02-18
EP2822953A1 (en) 2015-01-14
ME02630B (me) 2017-06-20
LT2822953T (lt) 2017-04-10
ES2621220T3 (es) 2017-07-03
PE20142339A1 (es) 2015-01-15
DK2822953T3 (en) 2017-04-03
ZA201406244B (en) 2015-05-27
BR112014022106B1 (pt) 2022-08-02
FR19C1062I1 (pt) 2019-11-22
GT201400187A (es) 2015-10-15
NZ627900A (en) 2016-08-26
CO7061081A2 (es) 2014-09-19
JP5823066B2 (ja) 2015-11-25
NI201400102A (es) 2015-03-05
CR20140370A (es) 2014-08-21
RS55814B1 (sr) 2017-08-31
HRP20170287T2 (hr) 2017-11-03

Similar Documents

Publication Publication Date Title
BR112014022106A2 (pt) derivados macrocíclicos para o tratamento de doenças
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1122611T1 (el) Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
MY191358A (en) Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
MX2013008868A (es) Nuevas azaindolifenil sulfonamidas como inhibidores de serina/treonina cinasa.
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
BR112012019765A2 (pt) composto, e, uso de um composto.
BR112013026397A2 (pt) Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer
EA201490888A1 (ru) Новые производные пурина и их применение для лечения заболевания
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201390520A1 (ru) Замещенные соединения пиридазинкарбоксамида
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2013, OBSERVADAS AS CONDICOES LEGAIS

B25G Requested change of headquarter approved

Owner name: PFIZER INC. (US)